Area of research
Hematology · Oncology
Research interest
Research interests include Multiple Myeloma Research and Treatments, Peptidase Inhibition and Analysis, Bone health and treatments, and Protein Degradation and Inhibitors.
Imaging in Plasma-Cell Neoplasms: Italian Experts' Recommendations.
A metabolic trade-off between malignant plasma cells and mesenchymal stromal cells sustains multiple myeloma growth
High glutamate levels in the bone marrow of multiple myeloma patients promote osteoclast formation: a novel target for osteolytic bone disease.
Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma.
Identification of clinical-biological features of newly diagnosed early relapse multiple myeloma patients eligible for autologous stem cell transplantation.
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
The Metabolic Features of Osteoblasts: Implications for Multiple Myeloma (MM) Bone Disease.
Vacuolated and signet-ring plasma cells in Waldenström macroglobulinemia.
The impact of CD56 expression in smoldering myeloma patients on early progression.
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy.
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response.
Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma.
A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors.
Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy.
Role of 1q21 in Multiple Myeloma: From Pathogenesis to Possible Therapeutic Targets.
A Simplified SARS-CoV-2 Pseudovirus Neutralization Assay.
PD-L1/PD-1 Axis in Multiple Myeloma Microenvironment and a Possible Link with CD38-Mediated Immune-Suppression.
Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score.
The Role of Proteasome Inhibitors in Multiple Myeloma Bone Disease and Bone Metastasis: Effects on Osteoblasts and Osteocytes
Oncolytic Virotherapy and Microenvironment in Multiple Myeloma.
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability.
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents
The Circular Life of Human CD38: From Basic Science to Clinics and Back.
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials
CD14<sup>+</sup> CD16<sup>+</sup> monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy.
Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma.
Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy.